Best of UEG Week 2022
Navigating the Evolving Therapeutic Landscape for IBD

Certification period for this program has expired. No credit will be offered beyond the program dates noted on the bottom of this page.

This activity is jointly provided by Global Education Group and Bonum CE in partnership with MondayNightIBD and United European Gastroenterology.

Supported by an educational grant from AbbVie & Bristol Myers Squibb.

Program Schedule

  • Saturday, 28 Jan 2023

    10:00 EST/15:00 GMT/16:00 CEST
    VIDEO WEBINAR
    Hosted on MondayNightIBD (Twitter), my_UEG (Twitter), BonumCE (Twitter)

  • Monday, 30 Jan 2023

    14:00 EST (2p)/19:00 GMT/20:00 CEST
    LIVE Q&A with program faculty
    Hosted on MondayNightIBD (Twitter)

Program Overview

This Twitter-hosted, video-based activity will highlight the top 10 IBD-focused abstracts presented at UEG Week 2022. The goal is to improve the familiarity of gastroenterologists and other healthcare professionals (HCPs) involved in the treatment of patients with IBD to the most current data regarding new and emerging treatments for IBD including:

  • proposed mechanisms of action and clinical evidence for new and emerging therapies

  • the latest efficacy and safety profile of each medication (both as monotherapy and in combination)

  • timeline for response

  • durability of response

  • suitability based on patient characteristics

  • patient related outcomes as clinical trial benchmarks

Armed with this information, clinicians will be better equipped to integrate these new and emerging therapies into clinical practice and close key knowledge and/or practice gaps around care and management of patients with IBD. The abstracts reviewed during this program are noted below. 

Abstracts to be discussed

  • EXTENDED THERAPY WITH OZANIMOD FOR DELAYED RESPONDERS TO OZANIMOD IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: DATA FROM THE TRUE NORTH OPEN-LABEL EXTENSION STUDY

  • ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

  • CLINICAL OUTCOMES OF INCREASED VERSUS CONVENTIONAL ADALIMUMAB DOSE INTERVALS IN PATIENTS WITH CROHN’S DISEASE IN STABLE REMISSION: THE RANDOMISED CONTROLLED LADI TRIAL

  • REAL WORLD EVIDENCE OF TOFACINITIB IN ULCERATIVE COLITIS: SHORT AND LONG-TERM EFFECTIVENESS, SAFETY AND IMPACT OF EXTRAINTESTINAL MANIFESTATIONS AND IMMUNOMEDIATED DISEASES

  • EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: FINAL RESULTS FROM THE PHASE 3 U[1]ACHIEVE MAINTENANCE STUDY

  • TO THE SOURCES OF INFLAMMATORY BOWEL DISEASE: PRE-HISTORIC INTRODUCTION OF IL-23 RECEPTOR RELATED GENETIC SUSCEPTIBILITY TO INFLAMMATION INTO TODAY'S EUROPEAN POPULATION

  • 52-WEEKS RISANKIZUMAB SUBCUTANEOUS MAINTENANCE DOSING IS EFFICACIOUS AND WELL TOLERATED IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO HAD DELAYED RESPONSE TO 12-WEEKS IV RISANKIZUMAB INDUCTION

  • IMPROVEMENT IN FATIGUE WITH MIRIKIZUMAB THERAPY IS ASSOCIATED WITH IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

  • INDUCTION COMBINATION THERAPY WITH GUSELKUMAB AND GOLIMUMAB FOLLOWED BY GUSELKUMAB MONOTHERAPY MAINTENANCE: RESULTS OF THE PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PROOF-OF-CONCEPT VEGA STUDY

  • MATCHING-ADJUSTED INDIRECT COMPARISONOF UPADACITINIB VERSUS VEDOLIZUMAB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Faculty

Aline Charabaty, MD, AGAF, FACG (chair)
Assistant Professor of Medicine
John Hopkins School of Medicine
Clinical Director of the IBD Center
Johns Hopkins - Sibley Memorial Hospital
Washington, D.C.

Iris Dotan, MD Chief, Division of Gastroenterology
Rabin Medical Center, Petah Tikva, Israel
Sackler Faculty of Medicine
Tel Aviv University, Israel
Chair, International Organization for the study of IBD (IOIBD)

Charles Murray, MA, MBBS, PhD, FRCP
Consultant Gastroenterologist
Department Chair of Gastroenterology
Digestive Disease and Surgery Institute
Cleveland Clinic London Hospital
Consultant Physician and Gastroenterologist, Clinical Director for Gastroenterology and Endoscopy, Royal Free London NHS Foundation Trust
London, England

Miguel Regueiro, MD
Professor and Chair of Cleveland Clinic’s Digestive Disease & Surgery Institute
Chair of the Department of Gastroenterology, Hepatology & Nutrition
Cleveland Clinic
Cleveland, OH

Target Audience

Gastroenterologists (GIs), GIs in training, surgeons, subspecialists such as dieticians and psychologists, nurse practitioners (NPs), physician assistants (PAs), nurses, and other healthcare team members involved in or interested in the care of patients with IBD.

Learning Objectives

After completing this activity series, the participant should be better able to:

  • Compare study design and clinical trial benchmarks among relevant studies of UC and CD and their implications for interpreting results.

  • Describe efficacy and safety data of emerging agents in clinical trials of UC and CD.

  • Select treatment that optimizes outcomes of patients with UC or CD based on the known safety and efficacy profiles of current therapies.

Disclosure of Relevant Financial Relationships

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

 

  • Aline Charabaty, MD, AGAF, FACG
    Advisory Board & Consulting: AbbVie, Bristol Myers Squibb, Janssen, Lilly, Pfizer, Takeda

    Miguel Regueiro, MD
    Advisory Boards & Consulting Fee: Abbvie, Alfasigma S.p.A., Allergan, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Genentech, Gilead, Janssen, Miraca Labs, Pfizer, Prometheus, Salix, Seres Therapeutics, Takeda, Target PharmaSolutions, UCB

    Charles Murray, MA, MBBS, PhD, FRCP
    Consulting fee: Abbvie, Ferring, Galapagos, Janssen
    Honoraria: AbbVie, Ferring, Galapagos, Janssen

    Iris Dotan, MD
    Consulting: Abbott, Abbvie, Altman, Arena, Athos, BMS, Cambridge Healthcare, Celgene, Celltrion, Genentech/Roche, Gilead, Galapagos, Eli-Lilly, Food industries organization, Integra Holdings, Iterative Scopes, Janssen, Neopharm, Wild bio, Pfizer, Sangamo, Sublimity, Takeda
    Contracted Research: Altman Research, BMS
    Honoraria: Abbvie, Abbott, Arena, Athos, BMS, Celgene, Celltrion, Genentech/Roche, Gilead, Galapagos, Eli-Lilly, Food industries organization, Iterative Scopes, Janssen, Pfizer, Sangamo, Sublimity, Takeda
    Speakers’ Bureau: Abbvie, Abbott, BMS, Celgene, Celltrion, Falk Pharma, Ferring, Genentech/Roche, Gilead, Galapagos, Janssen, Pfizer, Takeda

  • Global Education Group planners, Bonum CE staff, and others involved with the planning, development, and review of the content for this activity have no relevant financial relationships to disclose.

Certification

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Bonum Continuing Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation
Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive AMA Credit & Fee Information

In order to receive credit for this activity, the participant must read the front matter, achieve a passing score of 75% on the post-test, complete the evaluation and application for credit form.

There is no fee to participate in this activity.

EACCME Reciprocity

Mutual recognition agreement with the American Medical Association (AMA): The UEMS-EACCME® and the AMA recognize each other’s CME credits since 2000.

E-learning activities need to be certified for credit by the process in place where the CME provider is based, i.e. AMA PRA Category 1 Credit™ for U.S. CME providers and ECMEC credit for organizations in countries that are represented by the UEMS.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group, collaborators, and faculty on this program do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimers

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

System Requirements

All Bonum CE digital activities require the following hardware/software to view and participate:

  • Internet connection (via PC or Mac desktop or laptop computer, tablet, mobile device, etc.)

  • PowerPoint and/or a PDF viewer may be required on some activities

We recommend a minimum of:

  • 128MB RAM

  • Processor speed of 500MHz or higher

  • 800x600 color monitor

  • Video or graphics card

  • Sound card and speakers

To actively participate in Bonum’s social media (SoMe)-based CME programs, learners will need to have an established account in good standing on that hosting SoMe site. Learners will need to be logged-in to the SoMe hosting platform.

Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Release date: January 28, 2023
Expiration date: January 28, 2024
Estimated time to complete activity: 1 hour